Full Text of PDF (492k)
Article in Japanese
Abstract
Case Report
A case of lung adenocarcinoma with long-term anti-tumor maintenance after the discontinuation of nivolumab due to polymyalgia rheumatica
Tsunetaka Murayamaa Kentaro Fukunagaa Yoko Hirayamab Tomoko Iriyamaa Yuto Katoa Yasutaka Nakanoa
aDivision of Respiratory Medicine, Department of Internal Medicine, Shiga University of Medical Science
bDepartment of Pulmonary Medicine, Nagahama City Hospital
ABSTRACT
A 71-year-old man was diagnosed as having a Stage IV (cT1aN0M1b) lung adenocarcinoma 4 years previously. The patient developed stiffness in both shoulders, fatigue, and low-grade fever after 12 courses of nivolumab. After detailed examination, he was diagnosed with polymyalgia rheumatica (PMR) precipitated by an immune-related adverse event. Nivolumab was discontinued, and oral prednisolone was started for the treatment of PMR. The patient attained remission with oral prednisolone. He maintained a partial response for about 1 year after the cessation of treatment for the lung adenocarcinoma. This case suggests that the development of PMR precipitated by nivolumab treatment may be associated with a good prognosis in non-small cell lung cancer.
KEYWORDS
Lung adenocarcinoma Nivolumab Immune-related adverse events (irAE) Polymyalgia rheumatica (PMR)
Received 4 Mar 2018 ／ Accepted 22 Aug 2018
AJRS, 7(6): 394-398, 2018
Copyright © The Japanese Respiratory Society All Rights Reserved.